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Abstract
Immunotherapy based on natural killer (NK) cell infusions is a potential adjuvant treatment for many cancers. Such
therapeutic application in humans requires large numbers of functional NK cells that have been selected and expanded
using clinical grade protocols. We established an extremely efficient cytokine-based culture system for ex vivo expansion of
NK cells from hematopoietic stem and progenitor cells from umbilical cord blood (UCB). Systematic refinement of this two-
step system using a novel clinical grade medium resulted in a therapeutically applicable cell culture protocol. CD56
+CD3
2
NK cell products could be routinely generated from freshly selected CD34
+ UCB cells with a mean expansion of .15,000 fold
and a nearly 100% purity. Moreover, our protocol has the capacity to produce more than 3-log NK cell expansion from
frozen CD34
+ UCB cells. These ex vivo-generated cell products contain NK cell subsets differentially expressing NKG2A and
killer immunoglobulin-like receptors. Furthermore, UCB-derived CD56
+ NK cells generated by our protocol uniformly
express high levels of activating NKG2D and natural cytotoxicity receptors. Functional analysis showed that these ex vivo-
generated NK cells efficiently target myeloid leukemia and melanoma tumor cell lines, and mediate cytolysis of primary
leukemia cells at low NK-target ratios. Our culture system exemplifies a major breakthrough in producing pure NK cell
products from limited numbers of CD34
+ cells for cancer immunotherapy.
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Introduction
Natural Killer (NK) cells are CD56
+CD3
2 large granular
lymphocytes that exert innate immunity against viral infections
and cancer [1]. NK cells recognize and subsequently react to
virus-infected and transformed cells without prior immunization,
basically through the balance of signals from inhibitory and
activating receptors [2]. Therefore, NK cells have been previously
described as promising effectors for adoptive immunotherapy
against cancer [3]. The anti-tumor potential of NK cells has been
best demonstrated during therapy of leukemia patients with
allogeneic stem cell transplantation (SCT). Ruggeri et al.
demonstrated that NK cell alloreactivity can control relapse of
acute myeloid leukemia (AML) without causing graft-versus-host
disease (GVHD) in the setting of HLA-mismatched haploidentical
allogeneic SCT [4]. In addition, haploidentical NK cell infusions
together with IL-2 in a non-transplantation setting have been
associated with complete hematologic remission in poor-prognosis
patients with AML [5]. These encouraging results point out that
allogeneic NK cell-based immunotherapy may be a promising
therapeutic strategy for AML in both the non-transplant and post-
transplant setting [5,6].
To date, most clinical studies exploiting allogeneic NK cells for
adoptive immunotherapy have been performed with NK cells
selected from leukapheresis products by immunomagnetic beads
selection protocols [7–12]. In order to circumvent limitations in
cell numbers, purity and state of activation of such blood-derived
NK cells, ex vivo expansion of NK cells with higher purity will
facilitate the infusion of a greater number of activated NK cells in
patients with a relatively large tumor burden or permits multiple
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9221NK cell infusions [8,13,14]. Therefore, development of innovative
strategies enabling the generation of clinically relevant NK cell
products with high cell numbers, high purity and functionality
promises a major breakthrough in NK cell-based immunotherapy.
In this study, we developed a cytokine-based method for large
scale expansion of functional CD56
+ NK cells from hematopoietic
stem and progenitor cells. Similar studies have been performed
previously focusing on either CD34
+ hematopoietic progenitor
cells (HPC) from bone marrow (BM) or umbilical cord blood
(UCB) [15–17]. However, most of these culture systems are
unsuitable for clinical application because of the use of animal
sera, animal-derived proteins and supportive feeder cell lines.
Furthermore, most of these methods yielded only limited NK cell
numbers for successful adoptive immunotherapy in cancer
patients. In order to surmount these shortcomings, we established
a two-step culture scheme in which we used a novel clinical grade
medium to generate more than 3 to 4-log fold-expanded
functional CD56
+ NK cells from freshly selected or cryopreserved
CD34
+ UCB cells, respectively. The CD56
+ NK cell products
generated by this method have a very high purity, contain various
NKG2A and killer immunoglobulin-like receptor (KIR) expressing
mature subsets and efficiently lyse AML and solid tumor cells.
These findings exemplify that this culture system could hold great
promise for the ex vivo generation of clinical grade NK cell
products for cellular immunotherapy against cancer.
Results
Ex vivo Progenitor Cell Expansion and NK Cell
Differentiation
The aim of this study was to develop an efficient cytokine-based
ex vivo culture system for the expansion of CD34
+ cells followed by
the subsequent log-scale generation of CD56
+CD3
2 NK cells. To
identify a suitable medium for clinical applicable expansion and
differentiation of NK cells, we tested different basal media using a
two-step in vitro differentiation scheme (Figure 1). Initially, we
compared the media H3000, Stemline I and Stemline II seeding
1610
4 CD34
+ cells using Method I. We detected a strong increase
in CD34
+ cell numbers in all three media, resulting in a mean
expansion rate for all experiments (n=15) of 4867 fold and
78627 fold after 1 and 2 weeks of culture, respectively. The total
cell expansion was associated with a gradual decline of the
frequency of CD34
+ cells from 84%616% at day 0 till 47%614%
at week 1 and 17%69% at week 2 (Figure S1a and S1b).
Next, we investigated whether the expanded UCB-derived
CD34
+ cells were able to differentiate into CD56
+ NK cells. The
differentiation step was monitored by the analysis of the cell
surface molecules CD34, CD117, CD56, CD94 and CD161,
which have been described to be expressed at different human NK
cell developmental stages in vivo [18]. We observed after 3 weeks
total culture duration that the percentage of CD34
+ cells further
declined, while the CD56
+CD161
+CD94
+ NK cell population
increased to 10–18% (e.g. Figure 2a). Thereafter, the population of
CD56
+CD161
+CD94
+ cells rapidly increased to 60–77% after 4
weeks and 80–96% after 5 weeks of culture (e.g. Figure 2a).
Although we could not detect significant differences between the
different basal media, the purity of the CD56
+ cell product
appeared slightly higher with H3000 medium (77%624%; n=3)
and Stemline I medium (75%621%; n=6) as compared to
Stemline II medium (66%617%; n=6) (Figure 2b). Furthermore,
a trend was observed towards higher CD56
+ cell numbers with
Stemline I medium (range 4610
6–1.1610
8 CD56
+ cells; n=6)
followed by H3000 (5.2610
6–5.4610
7 CD56
+ cells; n=3) and
Stemline II medium (range 1610
6–2610
7 CD56
+ cells; n=6)
(Figure 2c). The mean total cell expansion after 5 weeks of culture
with Stemline I medium was ,4,400-fold and with H3000
medium ,3,200-fold, but only ,850-fold expansion with Stem-
line II (Figure 2d). These results indicate that the culture
conditions support an effective outgrowth of CD56
+ NK cells
with a high purity of the final NK cell product after a culture
period of 5 weeks using various basal media.
Superior Expansion of Extremely Pure NK Cell Products
Was Achieved Using a Novel Clinical Grade Medium
Although high expansion rates and purities could be obtained
with current commercially available basal media, we were not
Figure 1. Schematic diagram of the different culture methods used for the ex vivo generation of CD56
+ NK cells from cytokine-
expanded CD34
+ UCB cells. In Method I–III different combinations of cytokines were tested as described in detail in Materials and Methods
starting with different numbers of initially seeded CD34
+ cells. In Method I and II, NK cells were generated from freshly selected UCB donors and the
culture duration was 5 weeks. In Method III, CD34
+ cells were used from cryopreserved UCB donors and the culture period was 6 weeks. Finally, the
diagram depicts which NK products were used and displayed as results in figures and supplemental material.
doi:10.1371/journal.pone.0009221.g001
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+ NK cell product following 5
weeks of culture using Method I (Figure 1). To further increase the
efficiency of our culture method, we tested a newly formulated
serum-free medium, designated Glycostem Basal Growth Medium
(GBGMH), which is produced under GMP conditions and suitable
for clinical applications. In addition, we slightly adjusted the
cytokine conditions during the expansion step, since we observed
that expansion of CD34
+ cells as well as total cells was most
prominent during the first week of culture (Figure S1a and S1c).
Furthermore, to increase the balance towards expansion of NK
cell progenitors we added IL-15 instead of TPO to the expansion
medium from day 9 of culture, and left out Flt3L in the
differentiation medium (Figure 1). Using this modified Method II,
culture in GBGMH resulted in the highest total cell expansion
during the first week and subsequent differentiation into CD56
+
NK cells (Figure 3 and Figure S1e). The total cell expansion rate in
Figure 2. Ex vivo generation of CD56
+ NK cells from cytokine-expanded CD34
+ UCB cells. CD34-enriched UCB cells were expanded for two
weeks using three different media (H3000, Stemline I and Stemline II) and subsequently differentiated into NK cells for three additional weeks in the
same basal medium using Method I (see Figure 1). Cell cultures were weekly analyzed for cell numbers and phenotype using FCM. (a) Representative
example of antigen expression during the two-step culture period using H3000 medium. One week after the onset of the NK cell differentiation step
2 (i.e. after 3 weeks total culture duration) the CD56
+CD161
+CD94
+ NK cell population increases and reaches high purity after 3 weeks of
differentiation (i.e week 5). (b) Mean CD56
+ cell frequency during the 5 week culture period for three different media, which have been tested in
parallel experiments using 3–6 UCB donors. (c) Mean total CD56
+ NK cell numbers after initial seeding of 1610
4 CD34
+ UCB cells during 5 weeks of
culture using Method I. Data represent a theoretical calculation based on the actual expansion rates of CD56
+ cells. Total yield of CD56
+ cells at each
week was calculated by multiplying the expansion rate per week with the number of cultured cells. (d) Mean fold expansion of total cells after initial
seeding of 1610
4 CD34
+ UCB cells during 5 weeks of culture using Method I. Data represent a theoretical calculation based on the actual expansion
rates of total cells.
doi:10.1371/journal.pone.0009221.g002
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(Figure 3a). More importantly, ex vivo generation of CD56
+ NK
cells in GBGMH yielded a significant higher purity of 99%61%
(n=3) compared to H3000 with 88%63% (n=3; p,0.05) and
Stemline I with 63%624% (n=3; p,0.05), respectively
(Figure 3b). These data demonstrate that the inventive modified
culture system using the newly formulated GBGMH medium
results in more than 4-log expansion of pure human NK cells from
freshly selected CD34
+ UCB cells.
Phenotypic Profile of CD56
+ NK Cells Derived from
Expanded CD34
+ Cells
Flow cytometric analysis revealed that the ex vivo-generated NK
cells after 5 weeks of culture contained a homogeneous cell
population displaying high expression of CD56 in the absence of
CD3 (Figure 4a). A high frequency of this CD56
+CD3
2 NK cell
population displayed expression of CD94, while only a limited
subset was positive for CD16. Furthermore, NK cell products
displayed homogeneous and relatively high expression of NKG2D
and the natural cytotoxicity receptors (NCR) NKp30, NKp44 and
NKp46, whereas NKG2A was more differentially expressed
(Figure 4b and Figure S2a). Additionally to these findings we
detected high expression of 2B4 (CD244) and NKR-P1 (CD161)
as typical NK cell receptors, while NKG2C and NKp80 were
absent or expressed at relatively low levels. In addition, we
observed high expression of MHC class I (HLA-ABC) and
cytokine receptor chains for IL-2 and IL-15 (CD122; IL-2/IL-
15Rb) and SCF (CD117; c-kit-R), which are important for NK cell
differentiation, expansion and activation.
KIR repertoire analysis showed significant individual differenc-
es in the frequency of KIR-expressing NK cell subsets between
various UCB donors. KIR
+ NK cell subsets could already be
Figure 3. Superior expansion of UCB-derived CD56
+ NK cells using a novel clinical grade medium. The new GBGMH medium was
compared with two previously tested media in the NK cell generation system according to Method II (see Figure 1). Cell cultures were weekly
analyzed for cell numbers and phenotype using FCM. (a) Fold expansion of total cells after initial seeding of 1610
4 CD34
+ UCB cells was determined
during 5 weeks of culture. Data represent the calculation based on the actual expansion rates of total cells and are displayed as mean 6 SD of three
different experiments. (b) CD56
+ cell frequency during the differentiation stage for three different media, which have been tested in parallel
experiments using three UCB donors. Data are depicted as mean 6 SD. * represents a p-value of ,0.05.
doi:10.1371/journal.pone.0009221.g003
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the end of the culture period at week 5 (Figure 4c and Figure S2b).
While some CD56
+ NK cell products contained positive cells for
all four KIR phenotypes analyzed (Figure 4c), others specifically
lacked the KIR2DL1/DS1
+ subset (Figure S2b). Generally, the
KIR2DL2/DL3/DS2
+ subset was present in a higher proportion
in all NK cell products analyzed so far, which is in agreement with
earlier observations that recovery of KIR2DL2/DL3/DS2
+ NK
cells is faster compared to the KIR2DL1/DS1
+ subset following
HSCT [19].
Taken together, these results illustrate that UCB-derived NK
cells generated with our optimized culture system contain
Figure 4. Phenotypical profile of ex vivo-generated NK cells using Method II with GBGM. (a) Flow cytometric analysis of a representative
NK cell product generated from CD34
+ UCB progenitor cells. Cells at 5 weeks of culture were analyzed for expression of CD56, CD3, CD94 and CD16.
(b) Expression of a repertoire of receptors important for regulating NK cell activity, including C-type lectin receptors, natural cytotoxicity receptors
and cytokine receptors. Histograms show expression of the antigen of interest (black histogram) compared to the specific isotype control (grey
histogram). (c) Acquisition of KIR
+ NK cell subsets during ex vivo NK cell generation from expanded CD34
+ UCB cells. KIR expression was determined
at week 4 and 5 during the differentiation step by FCM.
doi:10.1371/journal.pone.0009221.g004
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KIR and various activating receptors.
Ex vivo-Generated CD56
+KIR
+ and CD56
+NKG2A
+ NK Cells
Are Functionally Regulated by MHC Class I Expression
Phenotypic analysis showed that our ex vivo-generated NK cell
products contained up to 10% CD56
+KIR
+ cells and a high
proportion (40–60%) CD56
+NKG2A
+ cells. To determine
cytolytic activity of these subsets and investigate if this activity is
regulated by the expressed inhibitory receptors, we performed
CD107a-based degranulation assays using HLA-negative K562
cells and KG1a cells expressing relatively high levels of HLA-ABC
and -E (see Table 1). For these experiments, we used two ex vivo-
generated NK cell products that contained approximately 15–30%
CD56
+CD107a
+ cells upon co-culture with K562 (Figure 5 and
Figure S3). In contrast, KG1a cells hardly stimulated degranula-
tion of these NK cell products, indicating that cytolytic activity is
inhibited by HLA expression. Similarly, around 35% of the
CD56
+KIR2DL2/DL3
+ subset degranulated upon triggering by
K562, while only a small percentage (,5%) expressed CD107a
following co-culture with KG1a (Figure 5a and Figure S3). In
agreement with these results, degranulation by the
CD56
+KIR2DL2/DL3
+ subset could be specifically inhibited by
K562 cells transfected with the HLA-C group 1 allele HLA-Cw3,
while transfection of the HLA-C group 2 allele HLA-Cw4 allele
had not effect (Figure S4). Finally, we observed that also the
dominant CD56
+NKG2A
+ subset was able to efficiently degran-
ulate in response to K562 (28% CD107a
+ cells), while degranu-
lation towards KG1a was low probably due to relative high
expression of HLA-E molecules (Figure 5b and Table 1). These
data demonstrate that the KIR
+ and NKG2A
+ subsets within the
UCB-derived NK cell products are fully responsive mediating
strong degranulating activity, which is regulated by the expression
of MHC class I molecules on the engaged target cells.
Ex vivo-Generated NK Cells Efficiently Target Leukemia
and Solid Tumor Cells
To determine the cytotoxic potential of the ex vivo-generated NK
cell products, we performed flow cytometry-based cytotoxicity
assays using various myeloid leukemia cell lines (K562, Lama,
Kasumi and KG1a), primary AML cells and two melanoma cell
lines (BLM and FM3). Ex vivo-generated NK cells in GBGMH
mediated efficient lysis of K562 cells (,40% and ,90% after 4
and 24 hrs, respectively) at a very low E:T ratio of 2:1 (Figure 6a).
Furthermore, profound lysis could be observed against MHC class
I-expressing KG1a cells (,20% and ,40% after 4 and 24 hrs,
respectively). Interestingly, NK cells cultured in GBGMH showed
higher cytotoxic and degranulating activity as compared to NK
cells cultured in H3000 medium from the same UCB donor
(Figure S5a–c). Furthermore, we found that GBGM-derived NK
cells showed higher expression of the activating receptors
NKG2D, NKp30, NKp44 and NKp46 (Figure S5d).
In addition to effective lysis of K562, also the leukemia cell lines
Lama and Kasumi as well as the BLM and FM3 melanoma cells
were efficiently lysed by the NK cells (Figure 6d). Interestingly, a
monolayer of FM3 melanoma cells was completely destroyed
within one hour of co-culture with NK cells (Movie S1). High NK
cell-mediated cytolytic activity against leukemia and melanoma
cell lines was associated with a high percentage of CD107a
+ NK
cells (Figure 6b and 6e) and significant production of IFNc
(Figure 6c and 6f).
Finally, we investigated whether primary leukemia cells are
susceptible to killing by the ex vivo-generated NK cells. Therefore,
we performed cytotoxicity assays with AML cells from five
different patients. Primary AML cells from three patients (Pt 2, 4
and 5) were substantially killed within 3 days of co-culture at a low
E:T ratio of 3:1 albeit less potent than K562 cells (Figure 6g).
These results indicate that UCB-derived NK cells generated by
our efficient culture method have the ability to kill myeloid
leukemia and solid tumor cells.
Ex vivo Generation of NK Cell Products from Frozen
CD34
+ UCB Cells
To investigate whether our NK cell expansion protocol could be
adapted to a clinically applicable procedure, we have performed
experiments using GBGMH medium in which we left out LIF and
MIP-1a in the low-dose cytokine mixture because these cytokines
are not available clinical grade. Furthermore, we performed these
experiments using CD34
+ cells selected from thawed UCB
according to Method III depicted in Figure 1. Thawing and
CD34
+ cell selection resulted in obtaining 1.3060.61610
6 (range
0.84–2.50610
6) CD34
+ UCB cells from six donors (Table 2). Ex
vivo generation using Method III resulted in a calculated NK cell
yield of 4.662.4610
9 (range 1.9–7.8610
9) NK cells with a purity
of .95% after 6 weeks of culture (Table 2). The expansion rate
ranged between 1,500 and 6,500 fold starting with CD34
+ cells
from cryopreserved UCB. These data demonstrate that the
transfer of our described procedure to clinical applicable
conditions is feasible, and generates pure NK cell products with
a more than 3-log expansion potential.
Discussion
Here, we report a novel and highly potent two-step culture
method for the ex vivo generation of functional NK cells for clinical
application in the treatment of patients with AML and other
malignancies. We implemented a new clinical grade basal
medium, designated GBGMH, which facilitates efficient ex vivo
HPC and NK cell expansions. Our method enables the generation
of functional human NK cells more than 4-logs from CD34
+ cells
enriched from freshly collected UCB units and more than 3-log
from frozen UCB. To the best of our knowledge, this is the first
demonstration that human CD56
+ NK cells can be efficiently
generated ex vivo at such high log-scale magnitude.
Similar studies have been reported previously using different
combinations of cytokines with or without feeder cell lines and use
Table 1. HLA-C subtype, KIR group and cell surface
expression of HLA molecules by the different target cell lines.
Cell line HLA-Cw typing
1 KIR group HLA-ABC
2 HLA-E
2
K562 Cw*03, Cw*05 C1 & C2 ,12
KG1a Cw*04, Cw*16 C1 & C2 101 5
Lama Cw*05, Cw*12 C1 & C2 73 5
Kasumi Cw*03, Cw*08 C1 9 ,1
BLM Cw*07 C1 121 ,1
FM3 Cw*05 C2 132 6
1HLA-Cw typing was performed by SSO-PCR using sequence specific primers
according to ASHI guidelines.
2Expression of HLA molecules was measured by FCM and expressed as delta
MFI (= MFI specific antibody - MFI isotype control). HLA class A and B types of
the cell lines were: K562 (A*11, A*31, B*18, B*40), Lama (A*02, A*25, B*18,
B*44), Kasumi (A*26, B*40, B*48), KG1a (A*30, B*53, B*78), BLM (A*02, B*07)
and FM3 (A*02, B*44).
doi:10.1371/journal.pone.0009221.t001
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+ and NKG2A
+ NK cells to MHC class I-deficient target cells. Ex vivo-generated NK
cells using Method II with GBGM were incubated alone, or 18 hours with MHC class I-negative K562 or MHC class I-expressing KG1a cells at an E:T
ratio of 1:1. Cells were then stained for CD56, CD3, KIR or NKG2A, and the degranulation antigen CD107a. (a) Degranulation of total CD56
+CD3
2 NK
cells and KIR2DL2/DL3
+ NK cell subset expanded for 5 weeks from CD34
+ UCB cells. Density plots are gated on CD56
+CD3
2 NK cells and the
histogram plots show the CD107a degranulation of the KIR2DL2/DL3
+ NK cells. (b) Degranulation of total CD56
+CD3
2 NK cells and NKG2A
+ NK cell
subset expanded for 6 weeks from CD34
+ UCB cells. Density plots are gated on CD56
+CD3
2 NK cells and the histogram plots show the CD107a
degranulation of the NKG2A
+ NK cells.
doi:10.1371/journal.pone.0009221.g005
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study by Kao et al. showed that serum-free expanded CD34
+ cells
could be differentiated into a NK cell product with an average
purity of 40%–60% after 5–7 weeks of culture. They reached a
calculated mean expansion rate of 300-fold, but used fetal bovine
serum during the NK cell generation phase [16]. Compared to
Figure 6. Functional activity of ex vivo-generated CD56
+ NK cells using Method II with GBGM. (a) Specific cytotoxicity of a CD56
+ NK cell
product (98% purity) against the myeloid leukemia cell lines K562 and KG1a. Specific lysis was determined after 4 and 24 hours of co-culture in a
FCM-based cytotoxicity assay at an E:T ratio of 2:1. Data are displayed as mean 6 SD of triplicate wells. (b) Degranulation of CD56
+ NK cells was
determined by FCM as the percentage of CD107a
+ cells. Results are depicted as mean 6 SD of triplicate wells. (c) IFNc production was determined by
ELISA and depicted as mean 6 SD of triplicate measurements. (d) Specific cytotoxicity of another CD56
+ NK cell product (95% purity) against the
myeloid leukemia cell lines K562, Lama, Kasumi and KG1a, and the melanoma cell lines BLM and FM3. Specific lysis was determined after 18 hours of
co-culture in a FCM-based cytotoxicity assay at an E:T ratio of 1:1. Data are displayed as mean 6 SD of triplicate samples. (e) Degranulation of CD56
+
NK cells was determined by FCM as the percentage of CD107a
+ cells after overnight stimulation with different targets. Data are depicted as mean 6
SD of triplicate samples. (f) IFNc production was determined by ELISA and depicted as mean 6 SD of triplicate measurements. (g) Specific
cytotoxicity of a third CD56
+ NK cell product (97% purity) against primary AML cells from 5 different patients. Specific lysis was determined after 24,
48 and 72 hours of co-culture in a FCM-based cytotoxicity assay at an E:T ratio of 3:1. Data are displayed as mean 6 SD of triplicate samples.
doi:10.1371/journal.pone.0009221.g006
Expansion UCB-Derived NK Cells
PLoS ONE | www.plosone.org 8 February 2010 | Volume 5 | Issue 2 | e9221these recently published data, our novel culture system holds great
promise, resulting in more than 3-log-scale ex vivo generation of
NK cell products with nearly 100% purity using clinical grade
medium, human serum, and cytokines. The only cytokines that are
currently or in the near future not available as clinical grade
reagents are LIF and MIP-1a, which are part of the low-dose
supporting cytokine cocktail. However, experiments using CD34
+
selected cells from cryopreserved UCB revealed that these two
factors can be discarded without the loss of the NK cell
differentiation potential of our refined protocol (Table 2). Taking
the high expansion potential, our system allows the generation of
an average number of 4.6610
9 highly pure NK cells from frozen
CD34
+ UCB cells (Table 2). Moreover, preliminary upscaling
experiments in cell culture bags revealed that the established
culture procedure generates up to 2610
9 NK cells with the same
phenotype and function as shown for the NK cell populations
generated in tissue culture plates (data not shown). These findings
indicate that our refined ex vivo expansion protocol has the
potential to produce more NK cells (i.e. .2610
9 with a purity
between 95–99%) as compared to purification of mature NK cells
from a 15 liter lymphapheresis procedure, which yields
0.25610
960.14610
9 (range 0.01–0.47610
9) NK cells according
to the published data of McKenna et al. in 2007 [7–12].
The NK cell product generated by our method displayed
reproducibly an activated phenotype with a high expression of
CD56 and various activating receptors, such as NKG2D, NKp30,
Table 2. Overview of CD34+ cell selections and NK cell culturing procedures.
Method I - H3000 Method I - Stemline I Method I - Stemline II
CD34 (%) CD34 cells (610
6) CD56 (%) CD56 cells (610
9) CD56 (%) CD56 cells (610
9) CD56 (%) CD56 cells (610
9)
UCB1 78 1.10 50 0.57 74 1.20 87 2.20
UCB2 55 0.32 88 0.68 65 0.15 82 0.15
UCB3 93 0.52 94 3.10 43 0.55 71 0.50
UCB4 69 0.45 n.d. n.d. 99 3.50 57 0.12
UCB5 87 0.20 n.d. n.d. 75 0.40 48 0.02
UCB6 83 0.94 n.d. n.d. 97 10.0 49 0.12
mean 78 0.59 77 1.50 75 2.70 66 0.51
SD 14 0.36 24 0.14 21 4.00 17 0.82
range 55–93 0.20–1.10 50–94 0.57–3.10 43–99 0.15–10.0 48–87 0.02–2.20
median 81 0.49 88 0.68 75 0.90 64 0.14
Method II - H3000 Method II - Stemline I Method II–GBGM
CD34 (%) CD34 cells (610
6) CD56 (%) CD56 cells (610
9) CD56 (%) CD56 cells (610
9) CD56 (%) CD56 cells (610
9)
UCB7 68 0.50 91 11.0 40 0.69 98 7.7
UCB8 79 0.20 89 6.1 60 0.66 99 8.5
UCB9 96 0.24 85 3.4 88 3.20 100 18.0
mean 81 0.31 88 6.9 63 1.53 99 11.0
SD 14 0.16 3 4.0 24 1.50 1 5.5
range 68–96 0.20–0.50 85–91 3.4–11.0 40–88 0.69–3.20 98–100 7.7–18.0
median 79 0.24 89 6.1 60 0.69 99 8.5
Method III - GBGM
CD34 (%) CD34 cells (610
6) CD56 (%) CD56 cells (610
9)
UCB10 98 0.84 99 5.5
UCB11 96 1.20 96 1.9
UCB12 95 1.00 97 2.0
UCB13 88 0.92 95 4.0
UCB14 98 1.30 97 6.6
UCB15 98 2.50 97 7.8
mean 96 1.30 97 4.6
SD 4 0.61 1 2.4
range 88–98 0.84–2.50 95–99 1.9–7.8
median 97 1.10 97 4.7
Table 2 shows a summary of all different experiments and the corresponding UCB donors using the different culture methods I–III and media (see Figure 1). The purity
and the total number of CD34
+ cells after immunomagnetic selection determined by FCM are depicted for each UCB donor. The CD56 content after 5 weeks (Method I
and II) or 6 weeks (Method III) of culture was analyzed by FCM as described in Materials and Methods. Numbers of NK cells represent a theoretical calculation based on
the actual expansion rates of CD56
+ NK cells and were calculated using the initial numbers of CD34
+ cells from each UCB multiplied by the NK cell expansion rate from
each culture procedure. The mean 6 standard deviation (SD), range and median are calculated for each method and medium separately.
doi:10.1371/journal.pone.0009221.t002
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generated NK cells cultured in the presence of IL-2 and IL-15
showed a CD56
bright phenotype of which only a subset expressed
CD16 [20,21,25,26]. The resulting NK cell products contained
40–60% CD56
+NKG2A
+ NK cells and up to 10% of the CD56
+
population expressed various KIRs, though there was considerable
variation in the frequency of KIR
+ NK cell subsets between the
different UCB donors. According to the NK cell differentiation
model of Freud and Caligiuri, our ex vivo-generated NK cell
products predominantly contain developmentally mature NK cells
expressing high CD94/NKG2A, CD117 and/or KIR mediating
potent cytolytic activity against K562 cells [27]. A minority of the
CD56
+ NK cells in our products are phenotypically immature
lacking NKG2A and KIR. However, these immature NK cells
may have the potential to maturate in vivo following adoptive
transfer. Interestingly, Cooley et al. have shown that
CD56
+NKG2A
2KIR
2 NK cells are able to mature in vitro upon
culture with IL-15 and a stromal feeder cell line [28]. Phenotypic
analysis have revealed that UCB-derived NK cells generated with
our protocol display expression of cytokine receptors including IL-
2/IL-15Rb (CD122), which may promote in vivo survival,
expansion and maturation upon transfer following immunosup-
pressive therapy.
The strong cytotoxic activity of our UCB-derived NK cells
against various tumor cell lines as well as the cytolysis of primary
AML cells were displayed by specific lysis, CD107a-mediated
degranulation and the production of IFNc. Most experiments
were done with AML cell lines and primary AML cells, which has
been shown to be an attractive target for NK cell-mediated
immunotherapy [5,6]. Interestingly, we also observed efficient lysis
of melanoma cell lines, which strengthens the therapeutic potential
of our NK cells product also towards non-hematological cancers.
Most recently, several studies demonstrated, that NK cell-
mediated cytotoxicity and the use of NK cell-based immunother-
apy could be an efficient approach for the treatment of melanoma,
which was also demonstrated in a phase I trial using the NK-92
cell line [29–31].
In conclusion, the method presented here provides an important
advance for generating clinically relevant NK cell products from
hematopoietic stem and progenitor cells with high cell numbers,
high purity and functionality for use in NK cell-based immuno-
therapy. These ex vivo-generated NK cell products can be exploited
for adoptive immunotherapy either following haploidentical SCT
for boosting NK cell-mediated graft-versus-leukemia reactivity or
in the non-transplant setting following lymphodepleting immuno-
suppressive regimens. Our current NK cell generation protocol
has been optimized for the use of CD34
+ cells from UCB, which
can be readily obtained from cord blood banks. Furthermore, the
described modifications of our protocol and use of the GBGMH
medium have also enabled the generation of NK cells from bone
marrow or mobilized peripheral blood CD34
+ cells (preliminary
data not shown). Currently, our first aim is to explore the
feasibility of adoptive transfer of ex vivo-generated NK cell products
from KIR-ligand mismatched UCB donors in elderly patients with
AML following an intensive immunosuppressive regimen. Impor-
tant aspects to study in this trial are whether ex vivo-generated NK
cell products are able to survive, migrate and expand in vivo
following infusion into preconditioned patients.
Materials and Methods
Cell Lines
Cell lines (K562, KG1a, Lama, Kasumi, BLM and FM3) were
cultured in Iscove’s modified Dulbecco’s medium (IMDM;
Invitrogen, Carlsbad CA, USA) containing 50 U/ml penicillin,
50 mg/ml streptomycin and 10–20% fetal calf serum (FCS;
Integro, Zaandam, The Netherlands) Characteristics of the cell
lines used in functional assays are shown in Table 1. Clonal K562
cell lines expressing HLA-Cw*0301 and/or HLA-Cw*0403 were
used as target cells to analyze specificity of the UCB-derived NK
cells. Briefly, K562 cells were transfected with full length HLA-
Cw0301 cDNA inserted into the EcoRI and HindIII sites of
expression vector pcDNA3.1(2) (Invitrogen, Paisley, UK) and
HLA-Cw*0403 cDNA ligated into the pEF6/V5-His expression
vector using the TOPO TA Expression kit (Invitrogen). The cell
lines K562-Cw*0301, K562-Cw*0403 and K562-Cw*0301/0403
showed stable and strong HLA class I expression (.95%) analyzed
by flow cytometry (FCM) using the HLA class I antibody W6/32
(Sigma, Steinheim, Germany). The (co-)expression of HLA-
Cw*0301 and HLA-Cw*0403 was confirmed by sequencing of
HLA-Cw cDNA.
Selection of CD34-Positive Stem and Progenitor Cells
UCB units have been obtained at birth after normal full-term
delivery with written informed consent with regard of scientific use
from the cord blood bank of the Radboud University Nijmegen
Medical Center (RUNMC). UCB samples were stored at room
temperature and processed within 24 h after collection. Mononu-
clear cells (MNC) were isolated by Ficoll-Hypaque (1.077 g/ml;
GE Healthcare, Uppsala, Sweden) density gradient centrifugation.
Alternatively, UCB samples were thawed at 37uC and resus-
pended in CliniMACS buffer (Miltenyi Biotech, Bergisch
Gladbach, Germany) containing 5% HSA, 3.5 mM MgCl2 and
100 U/ml Pulmozyme (Genentech). After 30 min of incubation,
thawed UCB cells were washed and used for CD34
+ cell selection.
CD34
+ cells were selected from UCB cells using anti-CD34
immunomagnetic bead separation (Miltenyi Biotech, Bergisch
Gladbach, Germany) according to manufacturer’s instructions.
The cell number and purity of the enriched CD34
+ fraction was
analyzed by FCM. Purity of the obtained cell populations was
85613%.
Ex vivo Expansion of CD34-Positive Progenitor Cells
CD34
+ UCB cells (between 1610
4 and 3610
5 per ml) were
plated into 24-well tissue culture plates (Corning Incorporated,
Corning, NY) using Methods I, II or III (Figure 1) in the following
basal media: StemSpanH H3000 (Stemcell Technologies, Greno-
ble, France), Stemline I
TM and Stemline II
TM Hematopoietic
Stem Cell Expansion Medium (Sigma-Aldrich, Zwijndrecht, The
Netherlands) and Glycostem Basal Growth Medium (GBGMH)
(Clear Cell Technologies, Beernem, Belgium). H3000 and Stem-
line media were supplemented with 20 mg/ml ascorbic acid,
50 mmol/l ethanolamine, 50 mmol/l sodium selenite, 25 mmol b-
mercaptoethanol (all Sigma Aldrich), 100 U/ml penicillin,
100 mg/ml streptomycin and 2 mmol/L L-glutamine (all Invitro-
gen). All media used in Method I and II were supplemented with
10% human serum (HS; Sanquin Bloodbank, Nijmegen, The
Netherlands) and a low-dose cytokine cocktail consisting of 10 pg/
ml GM-CSF, 250 pg/ml G-CSF, 50 pg/ml LIF, 200 pg/ml MIP-
1a (all Stemcell Technologies) and 50 pg/ml IL-6 (CellGenix,
Freiburg, Germany), which was based on studies using the fetal
liver-derived stromal cell line AFT024 [32]. In Method III, LIF
and MIP-1a were left out of the low-dose cytokine mixture. In
addition, a high-dose cytokine cocktail was added consisting of
27 ng/ml SCF (CellGenix), 25 ng/ml Flt3L (CellGenix), 25 ng/
ml TPO (Stemcell Technologies) and 25 ng/ml IL-7 (Stemcell
Technologies). During the first 14 days of culture, low molecular
weight heparin (LMWH) (ClivarinH; Abbott, Wiesbaden, Ger-
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concentration of 25 mg/ml. In Method II and III, TPO was
replaced by 20 ng/ml IL-15 at day 9–14. Cell cultures were
refreshed with new medium every 2–3 days. Cultures were
maintained in a 37uC, 95% humidity, 5% CO2 incubator.
Differentiation of ex vivo Expanded CD34-Positive Cells
into NK Cells
Expanded CD34
+ UCB cells were differentiated and further
expanded using NK cell differentiation medium. This medium
consisted of the samebasal mediumas used for the CD34 expansion
step supplemented with 10% HS, the low-dose cytokine cocktail (as
previously mentioned) and a new high-dose cytokine cocktail
consisting of 20 ng/ml IL-7, 22 ng/ml SCF, 1000 U/ml IL-2
(ProleukinH; Chiron, Mu ¨nchen, Germany) and 20 ng/ml IL-15
(CellGenix). Flt3L (20 ng/ml) was only added to the differentiation
mediuminMethodI(Figure1).Mediumwasrefreshedtwice aweek
from day14onwards. Totaland CD56
+cellexpansionateachweek
of culture was calculated by the number of cultured cells divided by
the number of seeded cells. The number of seeded cells was reduced
by dilution with fresh differentiation medium. The theoretical total
cell numbers were calculated by multiplying the expansion rate per
week with the number cultured cells.
Flow Cytometry
Cell numbers and expression of cell-surface markers were
determined by FCM. Briefly, cells were incubated with the
appropriate concentration antibodies for 30 min at 4uC. After
washing, cells were resuspended in CoulterH IsotonH II Diluent
(Beckman Coulter) and analyzed using the Coulter FC500 flow
cytometer (Beckman Coulter). Cell numbers and NK cell purity
have been determined by gating on CD45
+ cells in combination
with forward scatter (FS) and side scatter (SS). For phenotypic
analysis of the NK cell products, living cells were gated only on
FS/SS and further analyzed with the specific antigen of interest.
The following conjugated antibodies were used: anti-CD16-FITC
(NKP15), anti-CD94-FITC (HP-3D9), anti-NKG2D-PE (1D11)
(BD Biosciences Pharmingen, Breda, The Netherlands), anti-
CD161-PE (191B8), anti-NKG2A-PE (Z199), anti-CD122-PE
(CF1) (Immunotech, Marseille, France), anti-NKG2C-PE
(134591), anti-NKp80-PE (239127) (R&D System, Abingdon,
UK), anti-CD45-ECD (J33), anti-CD117-PE-Cy5 (104D2D1),
anti-CD34-PE-Cy7 (581), anti-CD56-PE-Cy7 (N901), anti-
NKp30-PE (Z25), anti-NKp44-PE (Z231), anti-NKp46-PE
(BAB281), anti-CD158a,h-PE (EB6.B), anti-CD158b1/b2-PE
(GL183), anti-CD158e1/e2-PE (Z27), anti-CD158i-PE (FES172),
anti-CD3-ECD (UCHT1), anti-CD244-PE (C1.7), anti-CD25-PE-
Cy5 (B1.49.9), anti-CD7-PECy5 (8H8.1), anti-CD2-FITC
(39.C1.5) (all Beckman Coulter, Woerden, The Netherlands) and
anti-HLA-ABC-PE (W6/32) (Dako, Enschede, The Netherlands).
Flow Cytometry-Based Cytotoxicity and Degranulation
Studies
FCM-based cytotoxicity assays were performed as described
previously [33] with minor adaptations. Target cells were labeled
with 0.5 mM carboxyfluorescein diacetate succimidyl ester (CFSE;
Molecular Probes Europe, Leiden, The Netherlands) in a
concentration of 1610
7 cells per ml for 10 min at 37uC. The
reaction was terminated by adding an equal volume of FCS,
followed by incubation at room temperature for 2 min and stained
cells were washed twice with 5 ml IMDM/10% FCS. After
washing, cells were resuspended in IMDM/10% FCS to a final
concentration of 2610
5/ml. CD56
+ NK cells were washed with
PBS and resuspended in IMDM/10% FCS to a final concentra-
tion of 2610
5/ml. Target cells (2610
4) were co-cultured with
effector cells at different E:T ratio’s in a total volume of 200 ml
IMDM/10% FCS in 96-wells flat-bottom plates. NK cells and
target cells alone were plated out in triplicate as controls. NK cell
co-cultures with primary AML cells were supplemented with IL-3
(50 ng/ml), SCF (25 ng/ml), Flt3L (20 ng/ml), GM-CSF
(100 ng/ml) and G-CSF (100 ng/ml). To measure degranulation
by NK cells, anti-CD107a (H4A3; BD Biosciences) was added in a
1:200 dilution to the co-cultures. After incubation for 4 or 24 h at
37uC, 50 ml supernatant was collected and stored at 220uC for
later use to measure cytokine production. Cells in the remaining
volume were harvested and the number of viable target cells was
quantified by FCM. Target cell survival was calculated as follows:
% survival = {[absolute no. viable CFSE+ target cells co-cultured
with NK cells]/[absolute no. viable CFSE+ target cells cultured in
medium]}*100%. The percentage specific lysis was calculated as
follows: % lysis = {1002[% survival]}. Degranulation of NK cells
during co-culture was measured by cell surface expression of
CD107a [34]. After 2, 4 or 24 hrs of incubation at 37uC, the
percentage of CD107a+ cells was determined by FCM.
IFNc Production Assay
Production of IFNc by target cell-stimulated NK cells was
measured in the supernatant of the co-cultures by ELISA (Pierce
Endogen, Rockford, IL, USA). Absorbance was measured at
450 nm with a Multiscan MCC/340 ELISA reader (Titertek,
Huntsville, Alabama, USA).
Life Imaging NK Cell-Mediated Killing
NK cell-mediated killing of solid tumor cell lines was visualized
by life imaging on a Zeiss Axiovert 35 M inverted contrast
microscope (Zeiss, Sliedrecht, The Netherlands) which was placed
in a 37uC incubator. Images were digitized in 7686512 pixels with
a camera (VarioCam, PCO computer Optics GmbH, Kelheim,
Germany), coupled with the Pixel Pipeline in a Macintosh-G4.
Video recordings of microscopic fields were made continuously
(1 image/min) using an in house developed software program
version of the IPlab 3.5.5. image program (Scananlytics Inc. USA
All). Images were further processed using the NIH Image 1.61
program, resulting in a Quick-Time movie.
Statistics
Results from different experiments are described as mean 6
standard deviation of the mean (SD). Statistical analysis was
performed using ANOVA and Duncan Post-hoc comparison. A
p-value of ,0.05 was considered statistically significant.
Supporting Information
Figure S1 Expansion of CD34-enriched UCB cells using a
cytokine-based culture method. CD34
+ UCB cells were selected by
immunomagnetic beads and cultured for 2 weeks in three different
basal media supplemented with 10% HS, a low-dose cell
supporting cytokine cocktail, a high-dose cell expansion cocktail
and clinical grade low molecular weight heparin (see details in
Materials and Methods and Figure 1). Absolute CD34
+ cell
numbers (a), fold expansion of total cells (b) and CD34 content (c)
were determined by FCM after one and two weeks of culture using
Method I. CD34
+ cell numbers and fold expansion of total cells
using Method II (d+e). Data are depicted as mean 6 SD for the
different media, which have been tested in parallel experiments
with CD34
+ cells from 3–6 UCB donors.
Found at: doi:10.1371/journal.pone.0009221.s001 (6.73 MB TIF)
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using Method II with GBGM. (a) Flow cytometric analysis of a
second NK cell product generated from CD34
+ UCB progenitor
cells. Cells at 5 weeks of culture were analyzed for expression of
CD56, CD3, CD94 and CD16. (b) Expression of a repertoire of
receptors important for regulating NK cell activity, including C-
type lectin receptors, natural cytotoxicity receptors and cytokine
receptors. Histograms show expression of the antigen of interest
(black histogram) compared to the specific isotype control (grey
histogram). (c) Acquisition of KIR
+ NK cell subsets during ex vivo
NK cell generation from expanded CD34
+ UCB cells. KIR
expression was determined at week 4 and 5 during the
differentiation step by FCM.
Found at: doi:10.1371/journal.pone.0009221.s002 (7.08 MB TIF)
Figure S3 Responsiveness of ex vivo-generated KIR
+ NK cells
generated using Method II with GBGM to MHC class I-deficient
target cells. Ex vivo-generated NK cells were incubated alone, or
18 hours with MHC class I-negative K562 or MHC class I-
expressing KG1a cells at an E:T ratio of 1:1. Cells were then
stained for CD56, CD3, KIR, and the degranulation antigen
CD107a. Shown are the degranulation of total CD56
+CD3
2 NK
cells and KIR2DL2/DL3
+ NK cell subset expanded for 5 weeks
from CD34
+ UCB cells. Density plots are gated on CD56
+CD3
2
NK cells and the histogram plots show the CD107a degranulation
of the KIR2DL2/DL3
+ NK cells.
Found at: doi:10.1371/journal.pone.0009221.s003 (5.06 MB TIF)
Figure S4 Responsiveness of ex vivo-generated KIR
+ NK cells
generated by Method II to target cells expressing different KIR
ligands. Activity of UCB-derived NK cells derived from two
different donors were tested in a 2 hour CD107a degranulation
assay against K562 cells transfected with empty vector (EV), HLA-
Cw3 cDNA, HLA-Cw4 cDNA or both.
Found at: doi:10.1371/journal.pone.0009221.s004 (7.22 MB TIF)
Figure S5 Functional activity of ex vivo-generated CD56
+ NK
cells using Method II. (a) Specific cytotoxicity of two CD56
+ NK
cell products from the same UCB donor but cultured either in
H3000 or GBGM against the myeloid leukemia cell lines K562
and KG1a. Specific lysis was determined after 24 hours of co-
culture in a FCM-based cytotoxicity assay at an E:T ratio of 2:1.
Data are displayed as mean 6 SD of triplicate wells. (b)
Degranulation of CD56
+ NK cells was determined by FCM as
the percentage of CD107a
+ cells. Results are depicted as mean 6
SD of triplicate wells. (c) IFNc production was determined by
ELISA and depicted as mean 6 SD of triplicate measurements. (d)
Expression of activating receptors important for NK cell activity.
Histograms show antigen expression of GBGM-derived NK cells
(black histogram) compared to H3000-derived NK cells (grey
histogram) and the specific isotype control (white histogram).
Found at: doi:10.1371/journal.pone.0009221.s005 (8.74 MB TIF)
Movie S1 Movie showing the strong killing potential of ex vivo-
generated NK cells (bright spots) towards the adherent growing
melanoma cell line FM3 within one hour of co-culture. NK cells
were added to the melanoma tumor cell layer at an E:T ratio of
1:1.
Found at: doi:10.1371/journal.pone.0009221.s006 (1.43 MB AVI)
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